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Abstract 
Spatial learning and memory consolidation are important aspects of human cognition. The test for motor co-ordination in mice is to 
characterize the motor phenotype of animals and also in relation to human beings. It is among the most fundamental aspects of 
everyday life as each physiological process that must be performed in order to achieve movement. In this study, depressive effect 
and effect on learning and memory of the two hormones, melatonin and somatostatin on animals was evaluated using the loco-
motor activity test, rotarod and rectangular maze. The effect of Melatonin and Octreotide acetate alone and in combination with 
each other were estimated in Swiss albino mice. Melatonin was administered dose dependently and time dependently. Octreotide 
acetate was administered dose dependently. We compared the combined effect of these hormones for motor co-ordination, loco-
motor activity and for the memory and learning behavior of animals. As per the present study, we found significant changes in the 
motor co-ordination, learning, and memory and depressive effect in animals and there was potentiated depression and attenuated 
learning and memory when the hormones were used in combination. In-silco analysis was conducted using Patchdock software 
and molecular docking of the ligands to their respective receptors conducted. 
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Introduction 
Melatonin (MLT) is a naturally occurring hormone 
released from the pineal gland and also present in the 
gastrointestinal tract [1] found in most animals, including 
humans, and some other living organisms, including 
algae. Cloning studies have revealed two recombinant 
mammalian melatonin receptors - Mel1a and Mel1b, now 
termed MT1 and MT2 [2]. MT1 receptors signal via 
inhibitory G proteins (Gαi and Gαo) leading to adenyl 
cyclase inhibition and possibly inositol phosphate 
stimulation in recombinant systems [3, 4, 5]. Melatonin-
induced cytosolic calcium mobilization via PTX-
insensitive G proteins was confirmed in primary cultures 
of ovine pars tuberalis cells endogenously expressing 
Mel 1a receptors. Recombinant Mel 1a receptors were 
shown to activate potassium ion channels, to potentiate 
PGF2a-promoted stimulation of phospholipase C, and to 
modulate protein kinase C (PKC) and phospholipase A2 
via Gbg-subunits liberated during Gi/o protein activation [6]. 
Circulating levels vary in a daily cycle, and the role of 
endogenous melatonin in circadian rhythm disturbances 
and sleep disorders is well established. Melatonin 
receptors appear to be important in mechanisms of 
learning and memory in mice, and melatonin can alter 
electrophysiological processes associated with memory, 
such as long-term potentiation (LTP) [7]. The first 
published evidence that melatonin may be useful in 
Alzheimer disease was the demonstration that this 
neurohormone prevents neuronal death caused by 
exposure to the amyloid beta protein, a neurotoxic 
substance that accumulates in the brains of patients with 
the disorder [8]. Melatonin also inhibits the aggregation of 
the amyloid beta protein into neurotoxic micro aggregates 
which seems to underlie the neurotoxicity of this protein, 
causing death of neurons and formation of neurofibrillary 
tangles, the other neuropath logical landmark of 
Alzheimer disease. Melatonin has been shown to prevent 
the hyperphosphorylation of the tau protein in rats. On 
the other hand, studies in rats suggested that melatonin 
may be effective for treating Alzheimer's disease [8, 9].  
 
Vinita Ernest et al./Rec Res Sci Tech 2 (2010) 13-19 
 
On the other hand, Octreotide acetate (OA) is a 
long-acting octapeptide with pharmacologic actions 
mimicking those of the natural hormone somatostatin. It 
is an even more potent inhibitor of growth hormone, 
glucagon, and insulin than somatostatin. Octreotide and 
melatonin have been tried in rats for spinal cord injury in 
which melatonin was found to be superior to octreotide 
with respect to the prevention of congestion, edema, 
axonal degeneration and necrosis [10].   
Receptors of both these hormones come under the 
classification of G-protein Coupled Receptors. Melatonin 
receptors belong to class 1 or family A of GPCR. GPCR 
are involved in wide variety of physiological process. 
Their functions are extremely diverse as they regulate 
many physiological process related to neurological and 
neurodegenerative functions and metabolic control. The 
receptors in the mammalian brain bind several different 
neurotransmitters, including serotonin, dopamine GABA, 
opioid peptides, vasopressin, melatonin and glutamate. 
Melatonin may also affect clock gene protein levels in the 
adrenal cortex and influence adrenal functions [11]. Via its 
action upon two receptor subtypes called Mel1a (MT1) 
and Mel1b (MT2) receptor, melatonin may provide a 
feedback loop to the circadian clock in the SCN [11]. 
Keeping these considerations in mind, the primary 
objective of this study was to evaluate the effect of 
Melatonin on the motor co-ordination, loco-motor activity 
and memory and learning of animals. The secondary 
objectives were to evaluate the effect of Octreotide 
acetate on the motor co-ordination, loco-motor activity 
and memory and learning of animals and to evaluate the 
combined effect of  Melatonin and Octreotide acetate 
with each other for physiological effects such as motor 
co-ordination, loco-motor activity and memory and 
learning behavior of animals. The novelty of this study is 
the usage of the combination of the above mentioned 
drugs. The final objective of the present study was to 
evaluate model of structure of receptors which are not 
available in the Protein Data Bank (PDB) and to dock the 
structures of the receptors with the ligands (hormones). 
 
Materials and Methods 
Experiments were performed on female Swiss albino 
mice weighing 25-35g. They were obtained from 
Institutional Animal Centre of Christian Medical College, 
Vellore, India. Animals were divided into groups of 6-8 
and kept in separate polypropylene plastic cages under 
hygienic conditions, lined with paddy-husk bedding. 
These animals were housed in a colony room under 
controlled temperature (25±1ºc), relative humidity of 
(60±2%) and were exposed to a 12-h dark cycle, with 
food and water available ad libitum. All experiments were 
conducted during the light phase between 9.00 a.m. and 
4.00 p.m. The experimental protocol was approved by 
the Institutional Review Board (IRB) and care of animals 
was taken as per guidelines of CPCSEA, Department of 
Animal Welfare, Government of India.     
Drugs              
Melatonin Tablets were obtained from Aristo 
Pharmaceuticals Pvt. Ltd., Nani Daman, Daman (U.T) 
and Octreotide acetate (OTIDE) injection was obtained 
from United Biotech (P) Ltd., Bagbania, Solan, H.P., 
India.   
Methods 
(A) Rota-rod Test (Motor Co-ordination in mice): 
Rota-rod test is often used with the apparent assumption 
by the experimenters that it is a straightforward and 
simple assay of coordination. A Rota-rod tread mill 
device (Inco, India) was used for the evaluation of the 
effect of drugs on the motor coordination at speed of 20 
rotations per minute .Thirty minutes after administration 
of melatonin (180 µg/kg, 360 µg/kg, 540 µg/kg) i.p and 
Octreotide acetate (0.1 µg/kg, 0.2 µg/kg, 0.3 µg/kg) i.p. 
Each mouse was placed on the rotating rod for 5 min 
(300 secs). The endurance time for each mouse on the 
Rota-rod was noted. 
(B) Rectangular Maze Test: Maze studies helped 
uncover general principles about learning that can be 
applied to many species, including humans. Mazes are 
used to determine whether different treatments or 
conditions affect learning and memory in rats. Working 
concentration of the drugs i.e. Melatonin (540 µg/kg), and 
Octreotide acetate (0.2 µg/kg) was injected 
intraperitoneally and time taken to reach the chamber B 
of the rectangular maze was recorded.  
(C) Loco-motor Activity Test: The loco-motor 
activity of albino mice weighing between 25- 35 g were 
evaluated in an open field loco-motor box made of wood 
with dimensions (24×24×5) inch and comprising of 16 
squares. Loco-motor activity was estimated visually 
counting the no. of squares the animals crossed in 6 
mins. Mice were injected with one of the test drugs or its 
vehicle and were place in holding cage for 30 minutes for 
Melatonin and Octreotide acetate before testing. Each 
animal was tested once for the loco-motor activity [12]. 
Protocol of Experiments: 
Swiss albino mice were divided into four groups. Six 
in each group were employed in dose dependent and 
time dependent studies. The control and the test groups 
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of mice (n=6) were injected intraperitoneally (i.p.) either 
with saline (0.9% NaCl) or the drugs of graded doses 
respectively.  
Group 1: Served as control and was treated with 
normal saline. Equivolume of 0.9% NaCl was 
administered i.p. 
Group 2: Melatonin (180µg/kg, 360 µg/kg, 540 
µg/kg) was injected i.p. to eighteen mice for the study of 
dose dependent effect. Melatonin (540 µg/kg) was 
injected (I.P) to six mice to find the alteration of motor co-
ordination on rota-rod test was recorded after 15, 20, 30 
minutes of time and time dependent effect of melatonin 
was evaluated. 
Group 3: Octreotide acetate (0.1 µg/kg, 0.2 µg/kg, 
0.3 µg/kg) was injected (I.P) to eighteen mice for the 
study of dose dependent effect.  
Group 4: Combination of Drugs:   Octreotide 
acetate (0.2 µg/kg) + Melatonin (540 µg/kg) was injected 
(I.P) to six mice. After 30 minutes of Octreotide acetate 
injection, melatonin was administered and the fall off time 
of mice was recorded. 
In-Silico Analysis: Certain in-silico studies were 
done to check for the binding affinity of the receptors with 
the ligands. The 3D structures of the ligands were 
generated using CORINA software by obtaining the 
SMILES string from PUBCHEM. Then the receptors 
protein sequence was taken from SWISSPROT for the 
modeling using 3D JIGSAW and SWISSMODEL 
software. The docking of the 2 structures was done using 
PATCHDOCK.   
Statistical Analysis: For statistical evaluation of 
results and significance testing of group differences, the 
nonparametric Mann-Whitney U-test and Wilcoxon W test 
was performed. Results were considered to be of 
statistical significance at P≤0.05 (95% confidence 
interval). Data are presented as Means ± S.E.M.  
 
Results 
Results have been evaluated as percentage change 
in the various parameters of mice by comparison of pre-
drug values with post-drug values.  
 
A. ROTA-ROD ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Dose dependent effect of Melatonin compared with 
Saline (0.9% NaCl) 
 
 
Table 1. Time dependent study of Melatonin 
Pretreatment 
time Melatonin 
Fall off time (in secs) 
 Percent 
decrease 
Before drug After drug 
15 mins 101.6 46 54.72% 
20 mins 162.9 86 47.20% 
30 mins 98.6 73.1 25.86% 
 
(a) Effect of Melatonin on Rota-rod Test: The 
Dose dependent effect of the hormone has a highest 
percent decrease in fall-off time for the working 
concentration of 540µg/kg and it was noted to be 64.66% 
(figure 1). The time dependent effect was also depicted in 
table 1 and it is reported to be decreased by 54.72% for 
15 mins of pre-treatment time. 
(b) Effect of Octreotide acetate in Rota-rod Test: 
With increase in dosage, the fall-off time has decreased 
significantly for 0.3µg/kg and noted to be 44.01%. From 
the figure 2, it is clearly seen that the fall-off time has 
decreased apparently among the experimental group and 
increased when compared with saline. 
(c) Effect of Combination of Hormones on Rota-
rod Test: Octreotide acetate and Melatonin combination 
had a greater percent increase of 59.73% on the motor 
co-ordination of the Rotarod activity test over the other 
combinations. 
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Figure 2.  Dose dependent effect of Octreotide compared with Saline (0.9%NaCl) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (B) Rectangular Maze  
Table 2. Results of Rectangular maze 
 S. NO DRUG DOSAGE MEAN ± SEM 
1 Saline 0.2 ml 55.33 ± 3.938     
2 Melatonin 540 µg/kg 70.00 ± 10.739  ;  P<.05 
3 Octreotide acetate 0.2 µg/kg 71.33 ± 23.489   ;    NS 
4 Melatonin + Octreotide acetate 540 µg/kg + 0.2 µg/kg 68.00 ± 8.181     ;    NS 
NS= Not significant, P>.05 
(C) Locomotor activity  
Table 3. Results of Loco-motor activity 
S. NO DRUG DOSAGE IN ML MEAN ± SEM 
1 Saline 0.2 ml 110.17 ± 28.579 ;  
2 Melatonin 540 µg/kg 97.17 ± 2.892 ;    NS   NS 
3 Octreotide acetate 0.2 µg/kg 95.83 ± 26.872 ;  NS 
4 Melatonin + Octreotide acetate 540 µg/kg + 0.2 µg/kg 50.33 ± 8.106  ; P<.05 
NS= Not significant, P >.05 
 
 (a) Effect of Melatonin on loco-motor activity 
and memory and learning behavior of animals: The 
time taken to reach chamber B has significantly 
increased from 55.33 ± 3.938 sec to 70 ± 10.739 sec 
(Table 2) when compared with saline and the memory 
and learning process has been probably lowered down 
due to the sleeping effect caused by the drug melatonin. 
It is also noted that the loco-motor activity has been has 
decreased (Table 3) using the drug on comparison with 
saline from 110.17 ± 28.579 sec to 97.17 ± 2.892 sec 
moves in 6 min. The statistical significance of values 
obtained is shown in Table 2 and 3    
(b) Effect of Octreotide acetate on loco-motor 
activity and learning behavior of animals: As reported 
in Table 2, time taken to reach chamber B has a 
significant increase over saline from 55.33 ± 3.938 sec to 
71.33 ± 23.489 sec. The memory and learning activity is 
said to be apparently decreased with increase in time. It 
is seen that there is an apparent decrease in the no. of 
moves of the animal from 110.17 ± 28.579 sec to 95.83 
± 26.872 sec (Table 3). The statistical significance of 
values obtained is shown in Table 2 and 3 
 (c) Effect of combination of hormones on loco-
motor activity and learning behavior of animals: The 
time taken to reach chamber B for the animals 
administered with the combination of hormones was 
found to be increasing among the group in comparison 
with saline as reported in Table 2 for the memory and 
learning activity. The loco-motor activity has also seemed 
to vary among the group either decrease or increase in 
the no. of moves. It showed significant decrease in the 
administration of Octreotide acetate + Melatonin 
combination when compared with saline (Table 3). 
In-silico analysis: The score for the docked 
structures of the receptors with their ligands (hormones) 
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using the Patch-dock software was calculated. In the 
same way, Melatonin MT1 receptor binds the ligand 
Melatonin with a maximum score of 4598. Somatostatin 
receptor subtype 1 (SSTR1) has the highest score of 
7940 on binding Octreotide acetate, a potent analog of 
the growth hormone inhibitor Somatostatin. Another 
analog of Somatostatin named Lanreotide, has the 
maximum score for docking with the Somatostatin 
receptor subtype 3 (SSTR3) of 8438. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. (A) Docked structure of somatostatin receptor with octreotide  (B) Docked structure of melatonin receptor with melatonin 
Discussion 
The present study was conducted to ascertain the 
effect of the two hormones on neurobehavioral 
parameters. The results of the present study suggest that 
the combination of hormones has increased effect on the 
neurophysiological processes and increase the stability 
on the motor co-ordination and potentiated the 
depressive effects with both melatonin and octreotide the 
fall of time for rotarod was substantially decreased.These 
effects suggest their significant effects on the central 
nervous system. These results are in accordance to Shaji 
and Kulkarni [13] melatonin has been shown to have 
central nervous system depressant activities. There was 
marginal decrease in locomotor activity produced by 
melatonin and learning and memory was also reasonable 
reduced. These effects may be due to the prominent 
central nervous system effects of melatonin because 
melatonin receptors are present in the central nervous 
system [14]. MLT exert its physiological activities through 
the activation of series of G protein coupled receptors, 
two of which (MT1 and MT2) have been found in 
mammals, including humans and subsequently cloned. 
MT1 and MT2 receptors are expressed both centrally 
(SCN, cortex) and peripherally (kidney, adipocytes, retina, 
blood vessels). There is evidence that MT1 receptors 
might be implicated in sleep promoting effects of MLT. 
 These hormones bind to their respective GPCRs 
and stimulate the production of cGMP on the receptor 
region, which acts as a secondary messenger in the 
cascade thereby activating the G-proteins. The activation 
results in a cascade of signal transduction events such 
as stimulation or inhibition of adenylyl cyclase and 
activation of phospholipase C. These G-proteins in turn 
help in the production of nitric oxide (by endothelial NOS) 
which brings about vasodilation of the blood vessels and 
thus increasing the blood flow and relieving the 
depression and increasing the heart rate of the organism. 
They also stimulate the microtubules and change the 
physiological effect of the animal. On the other hand, 
when nitric oxide is produced by the inducible nitric oxide 
synthase (iNOS) by the cardiovascular system which is 
calcium independent, reverts the effect and induces 
depression and impairs motor co-ordination in animals. In 
Mt1-CHO cells, short melatonin exposure inhibited the 
cAMP-dependent signal transduction pathway, whereas 
after withdrawal from physiological melatonin exposure, a 
super sensitization of forskolin-induced cAMP formation, 
PKA activation, and phosphorylation of CREB were 
observed. Super sensitization of cAMP-dependent 
signaling cascades after agonist exposure has been 
shown for other inhibitory G protein-coupled receptors as 
well. The results of von Gall et al. [15] indicating that 
melatonin MT1-receptor knockout in the pars tuberalis 
(PT) has a blunting effect on the expression of PER1 
protein suggest that the melatonin MT1-receptor has a 
major rhythm-supporting role in this particular tissue, but 
obviously not, or not to the same extent, in pancreas and 
liver.  
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Melatonin GPCR signaling is generally a negative 
regulator of cell function via reduction of intracellular 
second messengers such as cAMP, Ca2+, and cGMP via 
Gαi/o subunits. The MTR 1/2 receptors activate G-protein 
alphaq (Gαq) subunits that stimulate phospholipase C, 
leading to DAG and IP3 actions. Melatonin regulates cell 
processes via nuclear signaling via transcription factors, 
RZR/ROR (RZR alpha and beta). Genes regulated by 
RZR/ROR include 5-lipoxygenase, p21WAF1/C1P1, 
apolipoprotein A-1, N-myc and Purkinje cell protein 2 [16]. 
On the other hand , Octreotide also produced a 
similar profile on locomotor activity and learning and 
memory process. When given together both melatonin 
and octreotide produced a synergistic effect on locomotor 
activity, learning and memory process. These actions of 
octreotide a surrogate of somatostatin may be attributed 
to the prominent CNS expression of somatostatin 
receptors and its effects on learning memory process [17]. 
The ligand binding domain for SST ligands is made up of 
residues in TMs111-V11 with a potential contribution by 
the second extracellular loop. SSTRs are widely 
expressed in many tissues including the central nervous 
system, frequently as multiple subtypes that coexist in 
the same cell. The five receptors share common 
signaling pathways such as the inhibition of adenyl 
cyclase, activation of phosphotyrosine phosphatase 
(PTP), and modulation of mitogen-activated protein 
kinase (MAPK) through G-protein-dependent 
mechanisms. Some of the subtypes are also coupled to 
inward rectifying K+ channels (SSTR2, 3, 4, 5), to 
voltage-dependent Ca2+ channels (SSTR1, 2), a 
Na+/H+ exchanger (SSTR1), AMPA/ kainate glutamate 
channels (SSTR1, 2), phospholipase C (SSTR2, 5), and 
phospholipase A2 (SSTR4) [18]. SSTRs block cell 
secretion by inhibiting intracellular cAMP and Ca2+ and 
by a receptor-linked distal effect on exocytosis. Some of 
the effects of somatostatin may attributed to its 
interaction with other neurotransmitters. Somatostatin 
receptors and dopamine receptors are co localized in 
neuronal subgroups, and somatostatin is involved in 
modulating dopamine-mediated control of motor activity 
[19]. Dopamine, somatostatin and angiotensin II receptors 
are negatively coupled to adenylate cyclase in anterior 
pituitary cells. Dopamine and somatostatin also directly 
modulate voltage-dependent calcium channels, perhaps 
through a direct coupling with potassium channels. It is 
also proved that the dopamine and somatostatin 
receptors appear coupled to various transduction 
mechanisms through pertussis-sensitive G proteins in 
anterior pituitary cells [20]. Since both the melatonin and 
somatostain are GPCRs its important to study their 
possible therapeutic actions. GPCRs have also been 
validated as therapeutic targets for a number of diseases 
based on the finding that naturally occurring mutations of 
the receptor can result in either a gain or loss of function 
of the receptor leading to an association with a disease 
state such as rhodopsin (retinitis pigmentosa), 
cholecystokinin-2 receptor (gastric carcinoid tumor), 
KSHV-GPCR (Kaposi’s sarcoma), chemokine receptor 
US28 (atherosclerosis), thyroid-stimulating hormone 
receptor (hyperthyroidism), luteinizing hormone receptor 
(precocious male puberty), parathyroid hormone receptor 
(dwarfism, hypercalcemia, hypophosphatemia), and 
calcium-sensing receptor (hypocalcemia). Thus, the 
importance of these hormones in neurobehavioral actions 
can be speculated based on our results.  The 
combination Melatonin and Octreotide acetate 
significantly increased the time to reach chamber B, 
thereby impairing the memory and learning behavior of 
animals (Table 2) and potentiated the depressive effect 
by decreasing the loco-motor activity of the animals 
(Table 3).  
The in-silico studies clearly suggest the good affinity 
of Octreotide and melatonin to its respective receptors. 
Molecular docking results suggest good affinity of the 
respective hormones to their respective receptors. 
 
Conclusion 
The results suggest that the motor co-ordination of 
animals is stabilized to a higher extent on administration 
of combination of hormones at the working concentration 
in the Rota-rod test. The loco-motor activity test 
conducted to check the depressive effect of the 
hormones also produced significant results proving that 
the hormones play a major role in the central nervous 
system acting as a depressant. The spatial learning and 
memory considered as the social behavior of animals has 
significantly decreased among the experimental mice 
group where the combination of hormones is 
administered.  
Melatonin has been shown to regulate intracellular 
concentrations of second messengers such as cAMP, 
calcium and Arachidonic acid. Under pathophysiological 
conditions such as inflammation, fever and immune 
reactions, however, melatonin, an endogenous negative 
regulator of cPLA2 (cytosolic phosphplipase A2), and its 
synthetic analogues may be explored as pharmaceutical 
agents to reduce abnormal activation of cPLA2. 
As reported that the somatostatin receptor subtypes 
1–5 (sst1–sst5) exhibit different intracellular trafficking 
and endosomal sorting after agonist exposure, they are 
highly expressed in neuronal as well as in non-neuronal 
tissues and tumors. They have complex overlapping 
patterns of expression.  This differential expression of 
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SSTRs in tumors and their ability to undergo 
internalization and desensitization paves the way for the 
clinical use of Somatostatin analogs in the near future. 
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